Etanercept in the treatment of rheumatoid arthritis.
Etanercept in the treatment of rheumatoid arthritis.
复制标题
DOI：
10.2147/tcrm.2007.3.1.99
复制
发表时间：
2007-03
影响因子：
2.8
通讯作者：
Bykerk V
中科院分区：
文献类型：
--
作者：
Haraoui B;Bykerk V
依那西普（ETN）是首个被批准用于治疗类风湿性关节炎（RA）的抗肿瘤坏死因子（TNF）药物。在过去的8年里，一些临床试验已经证明了它在建立和早期RA中的有效性和安全性，以及单药治疗或与甲氨蝶呤联合治疗。ETN不仅可以减轻RA的体征和症状，还可以延缓影像学损害的进展，改善患者的生活质量和功能。自第一次临床试验以来，它的安全性是可以预测的，没有新的重大安全问题。除治疗类风湿性关节炎外，ETN还可用于治疗银屑病关节炎。本报告回顾了RA和银屑病关节炎（PsA）的证据和数据。
Etanercept (ETN) is the first anti-tumor necrosis factor (TNF) agent to be approved for the treatment of rheumatoid arthritis (RA). Over the last 8 years, several clinical trials have shown its efficacy and safety in established and early RA, as well as a monotherapy or in combination with methotrexate. ETN not only reduces the signs and symptoms of RA, but also retards the progression of radiographic damage and improves the quality of life and function of patients. Its safety profile has been predictable since the first clinical trials with no new major safety concerns. Beyond its efficacy in RA, ETN is also indicated for the treatment of psoriatic arthritis. This current report reviews the evidence and the data in RA and psoriatic arthritis (PsA).